Skip to main content
. 2019 Jul 8;51(7):76. doi: 10.1038/s12276-019-0274-7

Fig. 6. Side effects in the control and sorafenib and apatinib treatment groups.

Fig. 6

a The 24-h urine creatinine (Crea) on day 20 post-treatment (n = 4). b The 24-h urine protein (UPro) on day 20 post-treatment (n = 4). c Mean blood pressure pretreatment and post-treatment (day 10) (n = 7). d Survival rate (n = 7). (*) P < 0.05, (**) P < 0.01, (***) P < 0.001, (ns) non-significant, P ≥ 0.05